MacroGenics, Inc.
9704 Medical Center Drive
Rockville
Maryland
20850
United States
Tel: 301-354-3758
Website: https://macrogenics.com/capabilities/
Email: collaborate@macrogenics.com
About MacroGenics, Inc.
MacroGenics is a biopharmaceutical company developing and manufacturing a portfolio of innovative antibody-based products intended to extend and enhance the lives of people with cancer. We achieve this by leveraging the skills, passion, and scientific expertise of our employees and partners. Part of this mission includes providing our expertise in biopharmaceutical development and manufacturing to CDMO clients via our FDA-licensed commercial manufacturing facility. Our GMP suite utilizes single-use technology for maximum speed and flexibility and is outfitted for production of mammalian drug substance at the 500 L or 2000 L scale. In addition to manufacturing, we offer a fully customizable CDMO package with optional development services and analytical testing.
MacroGenics is committed to redefining CDMO relationships through efficient collaboration, client prioritization and transparency. Ensuring your values align with our company culture is as important to us as ensuring your process fits our facility.
If you are interested in learning more about our CDMO capabilities, come check us out in Rockville, Maryland! Reach out to schedule a meeting and tour of our facility to discuss your CDMO needs.
Stock Symbol: MGNX
Stock Exchange: NASDAQ
255 articles about MacroGenics, Inc.
-
MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium
2/13/2023
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced preliminary safety and anti-tumor activity data from the dose expansion phase of the Company’s ongoing Phase 1 clinical trial of lorigerlimab, a bispecific, tetravalent PD-1 × CTLA-4 DART® molecule.
-
MacroGenics to Participate in Upcoming Investor Conferences - February 06, 2023
2/6/2023
MacroGenics, Inc. announced that the Company's management will participate in the following investor conferences in February 2023:
-
MacroGenics to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/4/2023
MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, announced that the company will participate in the 41st Annual J.P. Morgan Healthcare Conference.
-
MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors
1/4/2023
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointment of Dr. Margaret A. Liu and Meenu Chhabra Karson to its Board of Directors, effective January 3, 2023.
-
MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab
11/17/2022
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that the U.S. Food and Drug Administration announced the approval of the Biologics License Application (BLA) for teplizumab, an anti-CD3 monoclonal antibody that was previously developed by MacroGenics.
-
MacroGenics Provides Corporate Update and Third Quarter 2022 Financial Results
11/3/2022
MacroGenics, Inc. provided an update on its recent corporate progress and reported financial results for the quarter ended September 30, 2022.
-
MacroGenics to Participate in Upcoming November 2022 Investor Conferences
11/2/2022
MacroGenics, Inc. announced that the Company's management will participate in the following investor conferences in November 2022.
-
MacroGenics Announces Date of Third Quarter 2022 Financial Results Conference Call
10/26/2022
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2022 after the market closes on Thursday, November 3, 2022.
-
Gilead Sciences and MacroGenics entered into a licensing and collaboration pact worth up to $1.7 billion to develop a bispecific antibody to treat hematological cancers.
-
Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies
10/17/2022
Gilead Sciences, Inc. (NASDAQ: GILD) and MacroGenics (NASDAQ: MGNX) today announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific research programs.
-
MacroGenics to Participate in Upcoming September 2022 Investor Conferences
9/2/2022
MacroGenics, Inc. announced that the Company's management will participate in the following investor conferences in September 2022.
-
MacroGenics Provides Update on Corporate Progress and Second Quarter 2022 Financial Results
8/8/2022
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended June 30, 2022.
-
MacroGenics Announces Date of Second Quarter 2022 Financial Results Conference Call
7/25/2022
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the second quarter of 2022 after the market closes on Monday, August 8, 2022.
-
MacroGenics' Phase II trial shuts down after a patient death believed to be related to enoblituzumab combo, while Exelixis' Cabometyx combo improves PFS in renal cell carcinoma.
-
The study was assessing the investigational drug enoblituzumab as part of a combination therapy for head and neck cancer.
-
MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer
7/8/2022
MacroGenics, Inc. (NASDAQ: MGNX), today announced that effective as of July 7, 2022, the Company closed the Phase 2 study (CP-MGA271-06) evaluating the investigational regimen of enoblituzumab (Fc-optimized B7-H3-directed monoclonal antibody) in combination with either retifanlimab (anti-PD-1 monoclonal antibody) or tebotelimab (PD-1 × LAG-3 bispecific DART® molecule) in the first-line treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).
-
MacroGenics to Participate in Upcoming Investor Conference in June 2022
6/8/2022
MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, announced that the Company's management will participate in the following investor conference in June 2022.
-
MacroGenics Announces Appointment of William Heiden to Board of Directors
5/23/2022
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointment of William Heiden to its Board of Directors, effective May 22, 2022.
-
MacroGenics to Participate in Upcoming Investor Conference - May 17, 2022
5/17/2022
MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, announced that the Company's management will participate in the following investor conference in May 2022.
-
MacroGenics Provides Update on Corporate Progress and First Quarter 2022 Financial Results
5/3/2022
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended March 31, 2022.